Medimmune Limited

Humabs Biomed Sa

Gilad Kaplan

Davide Corti

Charles K Stover

Xiaodong Xiao

Elisabetta Cameroni

Martina Beltramello

Qun Wang

Meghan Pennini

Chew-shun Chang

Anna DeMarco

Jamese Johnson Hilliard

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering thepneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O2 antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO1 and induce opsonophagocytic killing of(e.g.,). The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O1 antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO2 and induce opsonophagocytic killing of(e.g.,) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Growing community of inventors

Gaithersburg, MD, United States of America

Gilad Kaplan